Our study suggested that cancer patients in T3-4 stages had lower levels of CD3+CD4+ T cells and CD19+ B cells, and patients in N2-3 stages had lower levels of CD19+ B cells and higher levels of IL-2. This evidence concerns the gene CD19 and cancer.